The most notable thing about TypeScript 6.0 is that it's going to be the last release based on the current JavaScript ...

Microsoft released TypeScript 6.0 on March 23, the last version built on the original JavaScript codebase, with three post-RC changes and a wave of deprecations designed to ready codebases for the ...

A long-awaited plaque honoring law enforcement officers who protected the Capitol during the Jan. 6, 2021, riot was installed on Saturday after a three-year delay. “On behalf of a grateful Congress, ...

I can't stand opening the Microsoft Store. It's slow to load, confusing to browse, and full of ads for things I don't care about. Luckily, thanks to a new feature, I don't have to open the Microsoft ...

Scientists have taken a major step toward mimicking nature’s tiniest gateways by creating ultra-small pores that rival the dimensions of biological ion channels—just a few atoms wide. The breakthrough ...

While Bethesda has made its position very clear on Fallout game locations (it'll never stray outside of the United States) that doesn't stop people dreaming about exploring irradiated wastelands in ...

Artificial-intelligence workloads are pushing semiconductor design to a point where traditional scaling strategies are running out of room. Performance improvements that once came from shrinking ...

DC Comics‘ latest major storyline, DC K.O., pits many of the universe’s strongest heroes and villains against each other in vicious battles. With the second round underway, the remaining characters ...

An advanced nuclear startup just achieved a milestone as it races to meet an ambitious Department of Energy goal. Founded just over two years ago in July 2023, El Segundo-based Valar Atomics announced ...

What are the facts behind the new spyware furor. Updated Nov. 18 with Samsung’s response to the AppCloud controversy. You may not have seen the headlines yet ...

Atom’s lingdolinurad (ABP-671), a URAT1 inhibitor, is in late stage global clinical trials for chronic gout and ABP-745, an anti-inflammatory drug, is in multi-country Phase 2 trials for acute gout ...